OncoMatch/Clinical Trials/NCT06942442
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Is NCT06942442 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Physician's Choice and Tebentafusp for hla-a*0201 positive cells present.
Treatment: Physician's Choice · Tebentafusp — This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Biomarker criteria
Required: HLA-A A*02:01 positive
HLA-A*02:01 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute Neutrophil Count (ANC) ≥ 1.5; Platelets ≥ 75
Kidney function
Serum creatinine ≤ 1.5 x institutional ULN or 24-hour creatinine clearance ≥ 50 ml/min (Cockroft formula acceptable)
Liver function
ALT and AST ≤ 2.5 x institutional ULN or ≤ 5.0 x institutional ULN if considered due to tumor; Alkaline phosphatase ≤ 2.5 x institutional ULN unless considered due to tumor; Serum bilirubin ≤ 1.5 x institutional ULN (patients with elevated bilirubin secondary to Gilbert's disease are eligible)
Adequate organ function within 28 days of Day 1 of study defined as: Absolute Neutrophil Count (ANC) ≥ 1.5; Platelets ≥ 75; ALT and AST ≤ 2.5 x institutional ULN or ≤ 5.0 x institutional ULN if considered due to tumor; Alkaline phosphatase ≤ 2.5 x institutional ULN unless considered due to tumor; Serum bilirubin ≤ 1.5 x institutional ULN. NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study; Serum creatinine ≤ 1.5 x institutional ULN or 24-hour creatinine clearance ≥ 50 ml/min (calculated creatinine clearance using Cockroft formula is acceptable)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Southern California - Norris Cancer Center · Los Angeles, California
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify